Remus Pharmaceuticals
Remus Pharmaceuticals Share Price Chart
Remus Pharmaceuticals last traded at ₹930.00 (2026-10-13). Over the past month the stock moved +4.1%, three months the stock moved +25.8%, year the stock moved +16.1%. Its closing range over 52 weeks is ₹612.75 – ₹988.80, with the latest close 5.9% below the high.
Closing prices up to 2026-10-13.
About Remus Pharmaceuticals
Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]
Business Overview:[1][2] RPL and its group of companies specialize in marketing pharmaceutical products with expertise in Critical Care, Neurology, Cardiology, and Diabetic categories, and recently getting off-patent molecules in various dosage forms and in complex generics. Company gets finished pharmaceutical formulations manufactured on loan license or contract manufacturing
Fundamentals
Quarterly Results
In the latest quarter (Mar 2026), Remus Pharmaceuticals reported sales of ₹453.00 crore (+144.9%) and net profit of ₹25.00 crore (+31.6%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 453.00 | 30.00 | 7.00 | 25.00 | 16.54 |
| Sep 2025 | 400.00 | 27.00 | 7.00 | 22.00 | 14.85 |
| Mar 2025 | 348.00 | 25.00 | 7.00 | 21.00 | 13.57 |
| Sep 2024 | 273.00 | 20.00 | 8.00 | 19.00 | 11.87 |
| Mar 2024 | 185.00 | 20.00 | 11.00 | 19.00 | 13.16 |
| Sep 2023 | 29.00 | 9.00 | 32.00 | 6.00 | 4.87 |
| Sep 2025 | Mar 2026 | |
|---|---|---|
| Sales growth | +1279.3% | +144.9% |
| Operating profit growth | +200.0% | +50.0% |
| Net profit growth | +266.7% | +31.6% |
| EPS growth | +204.9% | +25.7% |
| OPM % | 7.0% | 7.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Remus Pharmaceuticals reported sales of ₹854.00 crore (+37.7%) and net profit of ₹46.00 crore (+21.1%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 854.00 | 57.00 | 7.00 | 46.00 | 31.39 |
| Mar 2025 | 620.00 | 46.00 | 7.00 | 38.00 | 24.64 |
| Mar 2024 | 212.00 | 28.00 | 13.00 | 26.00 | 18.57 |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Sales growth | +192.5% | +37.7% |
| Operating profit growth | +64.3% | +23.9% |
| Net profit growth | +46.2% | +21.1% |
| EPS growth | +32.7% | +27.4% |
| OPM % | 7.0% | 7.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Remus Pharmaceuticals.
Get Free AI Stock Analysis FREE →Latest News
No recent news available for Remus Pharmaceuticals.
Frequently Asked Questions
What is Remus Pharmaceuticals's current stock price?
Remus Pharmaceuticals shares were last quoted at ₹930.00 (-4.7% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Remus Pharmaceuticals?
Remus Pharmaceuticals has a price-to-earnings (P/E) ratio of 23.47 and a price-to-book (P/B) ratio of 3.09. The industry P/E is 52.82.
What is the 52-week high and low of Remus Pharmaceuticals?
The 52-week high of Remus Pharmaceuticals is ₹1,007.00 and the 52-week low is ₹580.00.
What is the market cap of Remus Pharmaceuticals?
The market capitalisation of Remus Pharmaceuticals is about ₹1,083.54 crore.
How did Remus Pharmaceuticals perform in its latest quarterly results?
In the latest quarter (Mar 2026), Remus Pharmaceuticals reported sales of ₹453.00 crore (+144.9%) and net profit of ₹25.00 crore (+31.6%), compared with the same quarter last year.
Is Remus Pharmaceuticals a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Remus Pharmaceuticals has a 3-year ROE of 13.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Remus Pharmaceuticals?
Promoters hold about 70.95% of Remus Pharmaceuticals.
Which sector does Remus Pharmaceuticals belong to?
Remus Pharmaceuticals belongs to the Pharmaceuticals & Drugs sector.